MX363609B - Bencimidazoles triciclicos sustituidos como inhibidores de cinasas. - Google Patents

Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.

Info

Publication number
MX363609B
MX363609B MX2015005772A MX2015005772A MX363609B MX 363609 B MX363609 B MX 363609B MX 2015005772 A MX2015005772 A MX 2015005772A MX 2015005772 A MX2015005772 A MX 2015005772A MX 363609 B MX363609 B MX 363609B
Authority
MX
Mexico
Prior art keywords
substituted tricyclic
compounds
kinase inhibitors
tricyclic benzimidazoles
disclosed
Prior art date
Application number
MX2015005772A
Other languages
English (en)
Other versions
MX2015005772A (es
Inventor
Rzymski Tomasz
Zarebski Adrian
Dreas Agnieszka
Osowska Karolina
Kucwaj Katarzyna
Fogt Joanna
Cholody Marek
Czardybon Wojciech
Horvath Raymond
Wiklik Katarzyna
Milik Mariusz
Brzózka Krzysztof
Galezowski Michal
Original Assignee
Selvita Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selvita Sa filed Critical Selvita Sa
Publication of MX2015005772A publication Critical patent/MX2015005772A/es
Publication of MX363609B publication Critical patent/MX363609B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer compuestos bencimidazoles tricíclicos sustituidos, tal como se definen en este documento en la fórmula (I), o sales farmacéuticamente aceptables de los mismos. Los compuestos de la invención inhiben de manera selectiva a CDK8 y, por lo tanto, son útiles para tratar enfermedades relacionadas con esta cinasa, especialmente cáncer colorrectal y melanoma, y otras malignidades sólidas y hematológicas, enfermedades autoinmunes y enfermedades inflamatorias. También se dan a conocer procesos para preparar estos compuestos.
MX2015005772A 2012-11-08 2013-11-07 Bencimidazoles triciclicos sustituidos como inhibidores de cinasas. MX363609B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1220157.0A GB201220157D0 (en) 2012-11-08 2012-11-08 Substitute tricyclic benzimidazoles as kinase inhibitors
PCT/EP2013/073311 WO2014072435A1 (en) 2012-11-08 2013-11-07 Substituted tricyclic benzimidazoles as kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2015005772A MX2015005772A (es) 2015-11-18
MX363609B true MX363609B (es) 2019-03-28

Family

ID=47470315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005772A MX363609B (es) 2012-11-08 2013-11-07 Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.

Country Status (22)

Country Link
US (1) US9745299B2 (es)
EP (1) EP2917217B1 (es)
JP (1) JP6101812B2 (es)
KR (1) KR101812390B1 (es)
CN (1) CN104903321B (es)
AU (1) AU2013343550B2 (es)
BR (1) BR112015010019B1 (es)
CA (1) CA2890643C (es)
CY (1) CY1119084T1 (es)
DK (1) DK2917217T3 (es)
ES (1) ES2628046T3 (es)
GB (1) GB201220157D0 (es)
HR (1) HRP20170802T1 (es)
HU (1) HUE033485T2 (es)
IL (1) IL238693A0 (es)
LT (1) LT2917217T (es)
MX (1) MX363609B (es)
PL (1) PL2917217T3 (es)
PT (1) PT2917217T (es)
RS (1) RS56056B1 (es)
SI (1) SI2917217T1 (es)
WO (1) WO2014072435A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3133075B1 (en) 2014-04-18 2020-12-30 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
BR112018008931A8 (pt) 2015-11-03 2019-02-26 Lu License Ab ?compostos para tratamento de distúrbios hipoproliferativos?
JP7142846B2 (ja) 2017-01-30 2022-09-28 国立大学法人京都大学 新規化合物及び制御性ｔ細胞の製造方法
EP3591040A4 (en) * 2017-03-03 2020-11-11 Kyoto University METHOD FOR PRODUCING PANCREATIC ANALYZER CELLS
EP3607944A4 (en) * 2017-04-03 2020-11-18 Kyoto Pharmaceutical Industries, Ltd. NEW INHIBITOR OF THE CYCLINE-DEPENDENT KINASE 8 AND / OR 19
US11261184B2 (en) 2017-10-02 2022-03-01 Boehringer Ingelheim International Gmbh [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors
WO2020038387A1 (zh) * 2018-08-24 2020-02-27 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
EP3873896A4 (en) * 2018-12-14 2022-08-31 Jiangsu Hengrui Medicine Co., Ltd. TRICYCLIC COMPOUNDS AS STING AGONISTS AND METHODS OF MANUFACTURE AND MEDICAL USES THEREOF
EP4041236A4 (en) * 2019-10-03 2023-10-25 Dana-Farber Cancer Institute, Inc. TRICYCLIC KINASE INHIBITORS AND THEIR USES
CN111349094B (zh) * 2020-04-23 2021-02-02 杭州师范大学 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CN116391028A (zh) 2020-11-20 2023-07-04 千纸鹤治疗公司 促熟剂
KR20230145101A (ko) 2021-02-09 2023-10-17 오리즈루 세라퓨틱스 가부시키가이샤 성숙화제
TW202330910A (zh) 2021-09-27 2023-08-01 國立大學法人京都大學 Ｔ細胞的製造方法
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2899757B2 (ja) 1989-06-26 1999-06-02 持田製薬株式会社 ジヒドロイミダゾキノリノンオキシムスルホン酸誘導体
US5500423A (en) * 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
ES2233671T3 (es) * 2000-08-08 2005-06-16 Sanofi-Aventis Derivados de benzimidazol, su preparacion y aplicacion en terapeutica.
AU2002358650A1 (en) 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
WO2003104233A1 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
US20070032469A1 (en) 2005-08-05 2007-02-08 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
KR20080049130A (ko) * 2005-09-30 2008-06-03 아스트라제네카 아베 세포 증식 억제 활성을 갖는 이미다조 [1,2-ａ] 피리딘
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
MX2013008822A (es) * 2011-02-09 2013-10-07 Hoffmann La Roche Compuestos heterociclicos como inhibidores de cinasa fosfatidilinositol-3 (pi3).

Also Published As

Publication number Publication date
US9745299B2 (en) 2017-08-29
SI2917217T1 (sl) 2017-08-31
BR112015010019A8 (pt) 2019-09-17
HUE033485T2 (en) 2017-12-28
BR112015010019A2 (pt) 2017-07-11
KR20150091074A (ko) 2015-08-07
CY1119084T1 (el) 2018-01-10
CN104903321B (zh) 2017-10-24
JP6101812B2 (ja) 2017-03-22
AU2013343550B2 (en) 2016-09-22
IL238693A0 (en) 2015-06-30
MX2015005772A (es) 2015-11-18
LT2917217T (lt) 2017-07-25
BR112015010019B1 (pt) 2022-08-09
EP2917217A1 (en) 2015-09-16
PT2917217T (pt) 2017-06-07
AU2013343550A1 (en) 2015-05-14
KR101812390B1 (ko) 2017-12-26
US20150274726A1 (en) 2015-10-01
PL2917217T3 (pl) 2017-10-31
CA2890643C (en) 2018-05-22
GB201220157D0 (en) 2012-12-26
JP2016503408A (ja) 2016-02-04
EP2917217B1 (en) 2017-03-08
CA2890643A1 (en) 2014-05-15
WO2014072435A1 (en) 2014-05-15
ES2628046T3 (es) 2017-08-01
CN104903321A (zh) 2015-09-09
HRP20170802T1 (hr) 2017-08-11
RS56056B1 (sr) 2017-09-29
DK2917217T3 (en) 2017-06-19

Similar Documents

Publication Publication Date Title
MX363609B (es) Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12017502141A1 (en) Compounds and their methods of use
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX369589B (es) Derivados novedosos de bencimidazol como inhibidores de cinasas.
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX2012013197A (es) Inhibidores de indazol de cinasa.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX357502B (es) Derivados de pirrolotriazinona.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX336022B (es) Activadores de pkm2 bicíclicos.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX364859B (es) Derivados de imidazopirazinona.
MX2015012600A (es) Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
MX2016000487A (es) Piridina-2-carboxamidas como nematicidas.
NZ712369A (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
WO2014012902A3 (en) Melanosome transport inhibition for the treatment of melanoma
MY192305A (en) Bipyrazole derivatives as jak inhibitors
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази